Ning Gao, Fan Xing, Juan Du, Wenxue Zhao, Sijia Wang, Meinei Chen, Xiaolong Dong, Yiming Qi
Yan'an Medical College of Yan'an University, Yan'an, Shaanxi, China.
Yan'an Key Laboratory of Northern Shaanxi Tumor Prevention and Treatment, Yan'an Medical College, Yan'an University, Yan'an, Shaanxi, China.
Front Aging Neurosci. 2025 Aug 25;17:1637671. doi: 10.3389/fnagi.2025.1637671. eCollection 2025.
The intramembrane aspartic protease, γ-secretase, is a heterotetrameric protein complex composed of four integral membrane proteins: presenilin (PSEN), nicastrin (NCT), Anterior pharynx defective-1 (APH-1), and presenilin enhancer 2 (PEN-2). These components are sequentially assembled into a functional complex. γ-secretase is ubiquitously expressed in all cells and tissues and exhibits enzymatic activity akin to "molecular scissors" by cleaving various type I transmembrane proteins. The primary substrates of this complex include amyloid precursor protein (APP) and Notch. The role of APP in the pathogenesis of Alzheimer's disease (AD) has been extensively investigated. Although γ-secretase inhibitors (GSIs) have been evaluated for their therapeutic potential in AD, their clinical application is limited due to significant toxic side effects. Recently, γ-secretase modulators (GSMs) have emerged as promising alternatives, offering new opportunities for the treatment of AD, especially the inherent γ-secretase modulatory proteins (GSMPs) within cells. Research on GSMPs has ushered in a new era for mitigating the side effects of AD drugs. In this review, we systematically summarize recent advancements in the study of γ-secretase in relation to AD and provide an overview of GSMs and GSMPs, thereby offering potential insights for the development of therapeutic strategies for AD.
膜内天冬氨酸蛋白酶γ-分泌酶是一种异源四聚体蛋白复合物,由四种整合膜蛋白组成:早老素(PSEN)、尼卡斯特林(NCT)、前咽缺陷蛋白1(APH-1)和早老素增强子2(PEN-2)。这些组分依次组装成功能复合物。γ-分泌酶在所有细胞和组织中普遍表达,并通过切割各种I型跨膜蛋白表现出类似于“分子剪刀”的酶活性。该复合物的主要底物包括淀粉样前体蛋白(APP)和Notch。APP在阿尔茨海默病(AD)发病机制中的作用已得到广泛研究。尽管γ-分泌酶抑制剂(GSIs)已被评估其在AD治疗中的潜力,但由于显著的毒副作用,其临床应用受到限制。最近,γ-分泌酶调节剂(GSMs)已成为有前景的替代物,为AD的治疗提供了新机会,尤其是细胞内固有的γ-分泌酶调节蛋白(GSMPs)。对GSMPs的研究开创了减轻AD药物副作用的新时代。在本综述中,我们系统总结了γ-分泌酶与AD相关研究的最新进展,并概述了GSMs和GSMPs,从而为AD治疗策略的开发提供潜在见解。